We develop innovative therapeutics to protect and improve the vision of patients with a range of retinal diseases and conditions.

ONL Therapeutics is a clinical-stage biopharmaceutical company committed to helping patients see the future.

Clinical Trials

The company’s lead therapeutic candidate, ONL1204, is a first-in-class small peptide that is being studied in multiple diseases.


Our primary scientific focus is Fas-mediated signaling, initiated by the activation of the Fas receptor at the cell surface and implicated in a variety of diseases.

Month: June 2020

  • ONL Therapeutics featured on the OIS Retina Podcast

    ONL Therapeutics featured on the OIS Retina Podcast ANN ARBOR, MI – June 30, 2020 This week’s special guest on the OIS Retina Podcast is David Esposito, CEO of ONL Therapeutics. A West Point graduate who served as a platoon leader in the first Gulf War, Esposito began his career in ophthalmology as a pharmaceutical sales rep for…